Personalized Medicine in Ocular Fibrosis: Myth or Future Biomarkers.
Significance:Fibrosis-related events play a part in the pathogenesis or failure of treatment of virtually all the blinding diseases around the world, and also account for over 40% of all deaths. It is well established that the eye and other tissues of some group of patients, for example Afro-Caribbean people, scar worse than others. However, there is a current lack of reliable biomarkers to stratify the risk of scarring and postsurgical fibrosis in the eye.Recent Advances:Recent studies using genomics, proteomics, metabolomics, clinical phenotyping, and high-resolutionin vivoimaging techniques have revealed potential novel biomarkers to identify and stratify patients at risk of scarring in different fibrotic eye diseases.Critical Issues:Most of the studies, to date, have been done in animals or small cohorts of patients and future research is needed to validate these results in large longitudinal human studies. Detailed clinical phenotyping and effective biobanking of patient tissues will also be critical for future biomarker research in ocular fibrosis.Future Directions:The ability to predict the risk of scarring and to tailor the antifibrotic treatment regimen to each individual patient will be an extremely useful tool clinically to prevent undertreating, or exposing patients to unnecessary treatments with potential side effects. An exciting future prospect will be to use new advances in genotyping, namely next-generation whole genome sequencing like RNA-Seq, to develop a customized gene chip in ocular fibrosis. Successful translation of future biomarkers to benefit patient care will also ultimately require a strong collaboration between academics, pharmaceutical, and biotech companies.
National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology , London, United Kingdom .
Cynthia
C
Yu-Wai-Man
National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology , London, United Kingdom .
Peng Tee
PT
Khaw
biomarkers; fibrosis; genotyping; personalized medicine; phenotyping
Mol Biosyst. 2014 May;10(5):1055-62
24556753
Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2588-96
12766061
Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1772-82
12036978
Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5310-7
19494201
Br J Ophthalmol. 2000 May;84(5):506-11
10781515
Prog Retin Eye Res. 2002 Jan;21(1):127-44
11906814
Invest Ophthalmol Vis Sci. 2012 Apr 06;53(4):1764-72
22395890
Mol Vis. 2015 Aug 25;21:911-8
26321865
Invest Ophthalmol Vis Sci. 2012 Jun 28;53(7):4147-51
22661465
PLoS One. 2013 Aug 27;8(8):e72737
24015273
Nucl Med Rev Cent East Eur. 2015 ;18(1):35-6
25633515
Mol Vis. 2005 Jun 10;11:397-413
15988409
Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2897-904
12202508
Mol Vis. 2008 Jul 18;14:1327-37
18648525
Mol Vis. 2005 Dec 13;11:1083-100
16379021
Graefes Arch Clin Exp Ophthalmol. 1998 Apr;236(4):305-11
9561366
Arch Ophthalmol. 1994 Nov;112(11):1446-54
7980134
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4450-62
15557454
PLoS Negl Trop Dis. 2012;6(12):e1985
23285311
Am J Ophthalmol. 2007 May;143(5):873-5
17452175
Ophthalmology. 2013 May;120(5):978-83
23347982
Mol Vis. 2011;17:1891-900
21850163
Proteomics. 2015 Oct;15(19):3283-95
26058380
Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1174-81
15037585
Ophthalmology. 2001 Jul;108(7):1184-6
11425672
PLoS One. 2015 Apr 22;10(4):e0124492
25902199
Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1074-9
26011235
Invest Ophthalmol Vis Sci. 2012 Jun 28;53(7):4242-53
22618596
Br J Clin Pharmacol. 2013 Mar;75(3):619-29
22348240
Br J Ophthalmol. 2000 Sep;84(9):1056-7
10966966
PLoS One. 2015 Apr 16;10(4):e0122409
25879570
Mol Vis. 2002 Jun 15;8:196-204
12107411
Ophthalmology. 2007 Jan;114(1):47-53
17070581
J Ophthalmol. 2012;2012:542417
22970349
J Hepatol. 2013 Aug;59(2):236-42
23523583
Mol Vis. 2011 Mar 23;17:779-91
21527995
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8222-31
23150628
Ophthalmology. 2009 May;116(5):848-55
19268366
Invest Ophthalmol Vis Sci. 2013 Jun 21;54(6):4249-59
23696609
J Am Coll Cardiol. 2014 Mar 11;63(9):920-7
24161319
Infect Immun. 2011 Jan;79(1):499-511
20937763
Ann Rheum Dis. 2014 Feb;73(2):420-7
23511226
Chem Commun (Camb). 2015 Jul 14;51(55):11064-7
26069897
Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1616-21
12657600
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4377-83
18502995
Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2977-83
12202518
Mol Syst Biol. 2015 Jul 14;11(7):819
26174933
World J Gastroenterol. 2015 Jun 14;21(22):6931-6
26078570
Invest Ophthalmol Vis Sci. 2003 May;44(5):1998-2003
12714635
Arch Ophthalmol. 2007 Jul;125(7):977-8
17620585
Mol Vis. 2011;17:2634-48
22065916
J Glaucoma. 2004 Dec;13(6):454-60
15534469
Am J Pathol. 2009 Dec;175(6):2406-15
19910508
Respiration. 2006;73(2):197-202
16141712
J Biomed Opt. 2004 Jul-Aug;9(4):760-6
15250763
Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):40-51
18973845
Proteomics. 2013 Aug;13(16):2500-11
23749747
Sci Rep. 2014 Apr 09;4:4608
24714342
Mol Vis. 2007 Feb 02;13:164-73
17293780
Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec;31(6):338-9
23084017
Proteomics. 2008 Sep;8(17):3667-78
18752205
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):263-9
22436749
PLoS Negl Trop Dis. 2013 Aug 22;7(8):e2392
23991241
Eye (Lond). 2009 Sep;23(9):1859-65
18949008
PLoS Negl Trop Dis. 2015 May 13;9(5):e0003763
25970613
Ophthalmology. 2010 Dec;117(12):2353-8
20630596
Glycobiology. 2010 Jan;20(1):13-23
19736239
Hepatology. 2011 Jan;53(1):209-18
20890893
Arch Ophthalmol. 1994 Nov;112(11):1437-45
7980133
J Gastroenterol. 2013 Dec;48(12):1392-400
23478936
Trans Ophthalmol Soc U K. 1983;103 ( Pt 1):84-8
6581641
Prog Retin Eye Res. 2006 Jan;25(1):43-77
16005676
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8146-53
23139279
Surv Ophthalmol. 2000 Jul-Aug;45(1):49-68
10946081
PLoS One. 2013;8(1):e54191
23372684